Descripción de la empresa
Pelthos Therapeutics Inc. operates as a bio-pharmaceutical entity dedicated to developing and commercializing therapeutic products designed to address unmet treatment burdens for patients. The company functions within the healthcare sector, specifically focusing on the biotechnology industry, which implies a high-risk, high-reward environment centered on research and development of innovative medical solutions. Pelthos currently possesses a market capitalization of $75.47M and reported annual revenue of $16.80M, supported by an employee base of 92 individuals. These financial figures indicate that Pelthos is a small-cap biotechnology firm with a relatively modest revenue stream that is not yet generating significant profits, a common characteristic for companies in early-stage commercialization. The valuation suggests the company is priced based on future potential rather than current profitability, reflecting the typical lifecycle stage of a biotech firm reliant on capital markets to fund ongoing operations and product expansion.
Salud financiera
The company generated revenue of $16.80M over the trailing twelve months, yet this income was accompanied by a net income loss of $-43,319,000 and an EBITDA of $-29,123,000. The substantial gap between the positive revenue figure and the significant negative net income reveals a cost structure characterized by high operating expenses, likely driven by research and development costs or general administrative overhead typical of the biotech sector. Pelthos reported free cash flow of $-24,652,500, which indicates a lack of financial flexibility and a continued reliance on external financing to cover operational deficits. The company maintains a cash balance of $17.97M against total debt of $34.83M, resulting in a debt-to-equity ratio of 89.58, which signifies a highly leveraged balance sheet rather than a conservative one. Despite the negative income statements, the company holds a current ratio of 2.06, suggesting that it currently possesses sufficient short-term liquid assets to cover its short-term liabilities. However, the return on equity stands at -239.6% and the return on assets is -29.8%, metrics that reveal management has not yet achieved effectiveness in generating shareholder value or asset returns due to persistent operational losses.
Evaluación de valoración
The trailing twelve-month P/E ratio is N/A due to the company's negative earnings, while the forward P/E is listed at -52.30, implying that analysts do not expect a return to profitability in the immediate future based on current pricing models. The price-to-book ratio is 1.87, indicating that the market values Pelthos at a premium of 87% over its net asset value, a metric often seen in growth-oriented biotechnology firms where intangible assets are undervalued on the books. Alternative valuation metrics such as the price-to-sales ratio of 4.49 and the EV/EBITDA of -3.17 suggest that investors are pricing the stock primarily on top-line revenue generation rather than earnings power or discounted cash flow. The stock has traded between a 52-week low of $9.00 and a 52-week high of $54.29, meaning the current market price sits significantly below the yearly peak, reflecting market uncertainty regarding the company's clinical pipeline or commercial success. The beta value of 3.94 indicates that Pelthos exhibits extreme price volatility, moving nearly four times as much as the broader market index, which underscores the speculative nature of the investment in this specific asset class.
Growth & Income
Pelthos reports N/A for both revenue growth year-over-year and earnings growth year-over-year, reflecting the lack of historical data points or the non-sequential nature of its commercial launches. The absence of positive growth rates combined with the negative earnings profile implies that the company is not yet in a sustainable growth phase where earnings expansion outpaces revenue generation. As the dividend yield is N/A and the payout ratio is 0.0%, the company does not distribute income to shareholders, which is standard practice for biotech firms that must reinvest all available capital into research, development, and commercialization efforts. Consequently, the overall growth and income profile for Pelthos is defined by total reinvestment of resources to achieve future profitability rather than providing current income or consistent revenue expansion.